معرفی
Ben Morrow is a Senior Research Fellow in Medicinal Chemistry at Monash University, affiliated with the Faculty of Pharmacy and Pharmaceutical Sciences. His research focuses on the development of chemical probes and therapeutic agents targeting cancer and oxidative stress pathways.
His research interests include Medicinal Chemistry, Chemical Biology, Redox Biology, Drug Discovery, and Epigenetics. He develops innovative tools such as mitochondria-targeted redox probes and inhibitors of protein-protein interactions, particularly in cancer-related targets like KAT6A/B and WDR5.
The recent publication trends show a strong emphasis on targeted cancer therapies, bioactivation studies of drug candidates, and advanced imaging techniques for monitoring oxidative stress. His work bridges fundamental chemical design with biological application, contributing significantly to both chemical probe development and preclinical therapeutic discovery.
While no specific scientific awards are listed in the provided text, his work has been referenced in at least 15 patents and picked up by multiple news outlets, indicating translational impact.
Dr. Morrow collaborates extensively with large interdisciplinary teams, as evidenced by co-authorship on high-author-count papers, though specific grants or student supervision details are not mentioned. His work contributes to UN Sustainable Development Goals related to good health and well-being.
He is involved in collaborative research networks focused on drug discovery and chemical biology, working with experts in structural dynamics, toxicology, and cancer biology. His research outputs are highly cited, particularly his 2012 paper in the Journal of the American Chemical Society, which has over 120 citations.
